| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 694.75K | 961.68K | 259.35K | 184.16K | 449.62K | 536.36K |
| Revenue Growth % | - | 0.38% | -0.73% | -0.29% | 1.44% | 0.19% |
| Cost of Goods Sold | 682.89K | 975.96K | 1.46M | 2.55M | 3.04M | 3.61M |
| COGS % of Revenue | 0.98% | 1.01% | 5.62% | 13.83% | 6.76% | 6.74% |
| Gross Profit | 11.86K | -14.28K | -1.2M | -2.36M | -2.59M | -3.08M |
| Gross Margin % | 0.02% | -0.01% | -4.62% | -12.83% | -5.76% | -5.74% |
| Gross Profit Growth % | - | -2.2% | -82.87% | -0.97% | -0.1% | -0.19% |
| Operating Expenses | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M |
| OpEx % of Revenue | 0.09% | 0.04% | 2.77% | 1.23% | 4.8% | 3.74% |
| Selling, General & Admin | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M |
| SG&A % of Revenue | 0.09% | 0.04% | 2.77% | 1.23% | 4.8% | 3.74% |
| Research & Development | 682.89K | 975.96K | 1.46M | 2.55M | 0 | 0 |
| R&D % of Revenue | 0.98% | 1.01% | 5.62% | 13.83% | - | - |
| Other Operating Expenses | -682.89K | -975.96K | -1.46M | -2.55M | 0 | 0 |
| Operating Income | -53.79K | -56.86K | -1.92M | -2.59M | -4.75M | -5.08M |
| Operating Margin % | -0.08% | -0.06% | -7.39% | -14.06% | -10.56% | -9.47% |
| Operating Income Growth % | - | -0.06% | -32.69% | -0.35% | -0.83% | -0.07% |
| EBITDA | 0 | -53.69K | -1.86M | -2.59M | -4.74M | -5.08M |
| EBITDA Margin % | - | -0.06% | -7.17% | -14.05% | -10.55% | -9.47% |
| EBITDA Growth % | - | - | -33.62% | -0.39% | -0.83% | -0.07% |
| D&A (Non-Cash Add-back) | 53.79K | 0 | 0 | 0 | 1.69K | 2.89K |
| EBIT | -53.79K | -53.69K | -1.86M | -2.59M | -4.61M | -5.02M |
| Net Interest Income | -8.06K | -4.79K | -6.73K | -7.93K | 126.99K | 64.28K |
| Interest Income | 334 | 3.17K | 104 | 1.68K | 137.84K | 64.28K |
| Interest Expense | 8.39K | 7.96K | 6.83K | 9.61K | 10.85K | 0 |
| Other Income/Expense | -8.06K | -4.79K | 50.35K | -7.98K | 126.99K | 64.28K |
| Pretax Income | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M |
| Pretax Margin % | -0.09% | -0.06% | -7.19% | -14.11% | -10.27% | -9.35% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M |
| Net Margin % | -0.09% | -0.06% | -7.19% | -14.11% | -10.27% | -9.35% |
| Net Income Growth % | - | 0% | -29.26% | -0.39% | -0.78% | -0.09% |
| Net Income (Continuing) | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24 | -0.23 | -4.38 | -5.12 | -6.16 | -4.79 |
| EPS Growth % | - | 0.04% | -18.04% | -0.17% | -0.2% | 0.22% |
| EPS (Basic) | -0.24 | -0.23 | -4.00 | -5.12 | -6.16 | -4.79 |
| Diluted Shares Outstanding | 260K | 266.4K | 426.01K | 507.58K | 750.38K | 1.05M |
| Basic Shares Outstanding | 260K | 266.4K | 466.48K | 507.36K | 749.83K | 1.05M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 118.92K | 699.43K | 1.81M | 5.8M | 3.43M | 2.62M |
| Cash & Short-Term Investments | 26K | 606.74K | 1.71M | 5.12M | 3.29M | 2.18M |
| Cash Only | 26K | 606.74K | 1.41M | 5.12M | 3.29M | 2.18M |
| Short-Term Investments | 0 | 0 | 300.55K | 0 | 0 | 0 |
| Accounts Receivable | 83.89K | 69.03K | 0 | 113.66K | 32.29K | 84.71K |
| Days Sales Outstanding | 44.07 | 26.2 | - | 225.27 | 26.21 | 57.65 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K |
| Property, Plant & Equipment | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K |
| Fixed Asset Turnover | - | 3.76x | 1.27x | 1.22x | 3.04x | 9.47x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 118.92K | 955.02K | 2.01M | 5.95M | 3.58M | 2.67M |
| Asset Turnover | 5.84x | 1.01x | 0.13x | 0.03x | 0.13x | 0.20x |
| Asset Growth % | - | 7.03% | 1.11% | 1.96% | -0.4% | -0.25% |
| Total Current Liabilities | 165.67K | 207.77K | 340.63K | 1.18M | 385.36K | 754.42K |
| Accounts Payable | 49.34K | 24.54K | 46.9K | 384.36K | 138.02K | 388.19K |
| Days Payables Outstanding | 26.37 | 9.18 | 11.75 | 55.07 | 16.58 | 39.21 |
| Short-Term Debt | 50K | 82.04K | 25K | 275K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 40.04K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x |
| Quick Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 71.59K | 283.94K | 248.71K | 96.26K | 47.37K | 0 |
| Long-Term Debt | 50K | 50K | 50K | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 207.96K | 168.36K | 96.26K | 47.37K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 21.59K | 25.97K | 30.35K | 0 | 0 | 0 |
| Total Liabilities | 237.26K | 491.7K | 589.34K | 1.27M | 432.73K | 754.42K |
| Total Debt | 100K | 388.91K | 282.96K | 429.52K | 136.59K | 47.6K |
| Net Debt | 74K | -217.82K | -1.13M | -4.69M | -3.16M | -2.14M |
| Debt / Equity | - | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -6.41x | -7.14x | -280.34x | -269.42x | -437.50x | - |
| Total Equity | -118.34K | 463.32K | 1.42M | 4.68M | 3.14M | 1.92M |
| Equity Growth % | - | 4.92% | 2.07% | 2.28% | -0.33% | -0.39% |
| Book Value per Share | -0.46 | 1.74 | 3.34 | 9.21 | 4.19 | 1.83 |
| Total Shareholders' Equity | -118.34K | 463.32K | 1.42M | 4.68M | 3.14M | 1.92M |
| Common Stock | 520 | 574 | 387 | 574 | 605 | 121 |
| Retained Earnings | 0 | -1.24M | -3.11M | -5.7M | -10.32M | -15.34M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.18M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -39.12K | -28.58K | -989.27K | -1.83M | -3.15M | -3.95M |
| Operating CF Margin % | -0.06% | -0.03% | -3.81% | -9.94% | -7.01% | -7.37% |
| Operating CF Growth % | - | 0.27% | -33.62% | -0.85% | -0.72% | -0.25% |
| Net Income | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 1.69K | 2.89K |
| Stock-Based Compensation | 0 | 57.71K | 728.8K | 747.4K | 1.36M | 749.4K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 18.73K | 7.64K | -50.21K | 9.61K | 121.2K | 200K |
| Working Capital Changes | 14.34K | -32.28K | 197.61K | 9.52K | -9.11K | 113.23K |
| Change in Receivables | -43.78K | 14.86K | 69.03K | -113.66K | 0 | 0 |
| Change in Inventory | 0 | -14.86K | 0 | 113.66K | 0 | 0 |
| Change in Payables | 33.44K | -24.8K | 22.36K | 337.46K | -246.34K | 250.18K |
| Cash from Investing | 0 | 0 | -300.55K | 300.55K | -14.43K | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -14.43K | 0 |
| CapEx % of Revenue | - | - | - | - | 0.03% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -300.55M | 0 | 0 |
| Cash from Financing | 25K | 609.31K | 2.1M | 5.24M | 1.34M | 2.84M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -39.12K | -28.58K | -989.27K | -1.83M | -3.16M | -3.95M |
| FCF Margin % | -0.06% | -0.03% | -3.81% | -9.94% | -7.04% | -7.37% |
| FCF Growth % | - | 0.27% | -33.62% | -0.85% | -0.73% | -0.25% |
| FCF per Share | -0.15 | -0.11 | -2.32 | -3.61 | -4.22 | -3.77 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 11.36K | 11.91K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -35.75% | -197.73% | -85.18% | -118.13% | -198.12% |
| Return on Invested Capital (ROIC) | - | -42.4% | -533.98% | -1407.16% | - | - |
| Gross Margin | 1.71% | -1.48% | -461.71% | -1283.43% | -575.87% | -573.65% |
| Net Margin | -8.9% | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% |
| Debt / Equity | - | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x |
| Interest Coverage | -6.41x | -7.14x | -280.34x | -269.42x | -437.50x | - |
| FCF Conversion | 0.63x | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x |
| Revenue Growth | - | 38.42% | -73.03% | -28.99% | 144.15% | 19.29% |
| 2022 | |
|---|---|
| Grant Revenues | 184.16K |
| Grant Revenues Growth | - |
Lipella Pharmaceuticals Inc. (LIPO) reported $0.2M in revenue for fiscal year 2024. This represents a 75% decrease from $0.7M in 2019.
Lipella Pharmaceuticals Inc. (LIPO) grew revenue by 19.3% over the past year. This is strong growth.
Lipella Pharmaceuticals Inc. (LIPO) reported a net loss of $1.26B for fiscal year 2024.
Lipella Pharmaceuticals Inc. (LIPO) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Lipella Pharmaceuticals Inc. (LIPO) had negative free cash flow of $2.36B in fiscal year 2024, likely due to heavy capital investments.